AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10484047 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of tHcy with creatinine clearance
Number of subjects: 452
Study 10484047 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of tHcy with serum B12
Number of subjects: 452
Study 10484047 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of tHcy with folate
Number of subjects: 452
Study 10484047 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of tHcy with MMA
Number of subjects: 452
Study 10484047 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of tHcy with cystathionine
Number of subjects: 452
Study 8759408 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal color and pulsed Doppler measurements
Number of subjects: 40
Study 1771395 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen, 200 mg/day (50 mg q.i.d.) for 7 days
Number of subjects: 40
Study 1771395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7276189 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring‐Contract (MC)
Number of subjects: 0
Study 7276189 — intervention group
Group type: COMPARATOR
Intervention: Monitoring (M)
Number of subjects: 0
Study 7276189 — intervention group
Group type: COMPARATOR
Intervention: Attention‐Placebo (AP)
Number of subjects: 0
Study 30588849 — intervention group
Group type: EXPERIMENTAL
Intervention: Active 'blue' lighting intervention (λmax = 480 nm)
Number of subjects: 32
Study 30588849 — intervention group
Group type: COMPARATOR
Intervention: Placebo 'red' control (λmax = 640 nm)
Number of subjects: 32
Study 30588849 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention and control conditions
Number of subjects: 32
Study 26408395 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol mouth rinse (MEN) during exercise
Number of subjects: 11
Study 26408395 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice slurry ingestion (ICE) before exercise
Number of subjects: 11
Study 26408395 — intervention group
Group type: COMPARATOR
Intervention: No intervention (CON)
Number of subjects: 11
Study 26408395 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol mouth rinse (MEN)
Number of subjects: 11
Study 25159886 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate 20 mg
Number of subjects: 135
Study 25159886 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate 50 mg
Number of subjects: 135
Study 25159886 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate 70 mg
Number of subjects: 135
Study 25159886 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil 250 mg
Number of subjects: 135
Study 25159886 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatments (Lisdexamfetamine dimesylate and Armodafinil)
Number of subjects: 135
Study 25159886 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate and Armodafinil
Number of subjects: 135
Study 22754899 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone (group A)
Number of subjects: 16
Study 22754899 — intervention group
Group type: COMPARATOR
Intervention: Porcine bone in addition to autologous bone (group B)
Number of subjects: 16
Study 22754899 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 16
Study 20140088 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal waist-to-hip ratio (approximately 0.7) with redistributed body fat
Number of subjects: 0
Study 20140088 — intervention group
Group type: COMPARATOR
Intervention: Presurgical bodies (not optimal WHR)
Number of subjects: 0
Study 20140088 — intervention group
Group type: COMPARATOR
Intervention: Changes in BMI
Number of subjects: 0
Study 18541739 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrushing
Number of subjects: 290
Study 18541739 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-tooth extraction with amoxicillin prophylaxis
Number of subjects: 290
Study 18541739 — intervention group
Group type: COMPARATOR
Intervention: Single-tooth extraction with identical placebo
Number of subjects: 290
Study 16003653 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (10 g/d x 10 d presurgery to 5 g/d x 30 d postsurgery)
Number of subjects: 37
Study 16003653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 12404668 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 3
Study 10811324 — intervention group
Group type: COMPARATOR
Intervention: Euglycemia (blood glucose, 6 mmol/L)
Number of subjects: 10
Study 10811324 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia (blood glucose, 15 mmol/L)
Number of subjects: 10
Study 8665134 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated hookwire for localization of impalpable breast lesions
Number of subjects: 31
Study 8665134 — intervention group
Group type: COMPARATOR
Intervention: Conventional mammographic localizing wire
Number of subjects: 31
Study 1800430 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (OC) with levonorgestrel (LNG) and norethisterone acetate (NEA)
Number of subjects: 622
Study 1800430 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (OC) with levonorgestrel (LNG)
Number of subjects: 622
Study 1800430 — intervention group
Group type: COMPARATOR
Intervention: Women not on OC (control group)
Number of subjects: 622
Study 6616495 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU
Number of subjects: 51
Study 6616495 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC (5-FU, doxorubicin, and cyclophosphamide)
Number of subjects: 51
Study 31044688 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 275
Study 31044688 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to treatment
Number of subjects: 275
Study 31044688 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization of tumor growth
Number of subjects: 275
Study 31044688 — intervention group
Group type: EXPERIMENTAL
Intervention: Nausea/vomiting
Number of subjects: 275
Study 31044688 — intervention group
Group type: EXPERIMENTAL
Intervention: Diarrhea
Number of subjects: 275
Study 28256485 — intervention group
Group type: EXPERIMENTAL
Intervention: System B/Obtura
Number of subjects: 150
Study 28256485 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched-single-cone
Number of subjects: 150
Study 28256485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold lateral compaction with matched GP cone
Number of subjects: 150
Study 28256485 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral compaction with standardized GP cones
Number of subjects: 150
Study 28256485 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermafil filling
Number of subjects: 150
Study 26603258 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2126458 (GSK458) at a maximum tolerated dose (MTD) of 2.5 mg once daily or twice daily dosing.
Number of subjects: 170
Study 26603258 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2126458 (GSK458) at doses ranging from 0.1 to 3 mg once or twice daily.
Number of subjects: 170
Study 26603258 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2126458 (GSK458) at a maximum tolerated dose (MTD) of 2.5 mg once daily.
Number of subjects: 170
Study 26603258 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2126458 (GSK458) in patients with PIK3CA mutations.
Number of subjects: 170
Study 25170037 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative therapy (OMTh)
Number of subjects: 44
Study 25170037 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy (control)
Number of subjects: 44
Study 22183158 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium 50 mg kg(‐1)
Number of subjects: 20
Study 22183158 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 20
Study 20382272 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal drug delivery system (TDDS) of Carvedilol (CRV)
Number of subjects: 10
Study 20382272 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal drug delivery system (TDDS) of Hydrochlorothiazide (HCTZ)
Number of subjects: 10
Study 20382272 — intervention group
Group type: COMPARATOR
Intervention: Conventional immediate release oral tablets of Carvedilol (CRV)
Number of subjects: 10
Study 20382272 — intervention group
Group type: COMPARATOR
Intervention: Conventional immediate release oral tablets of Hydrochlorothiazide (HCTZ)
Number of subjects: 10
Study 17284744 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplement containing folate (1 mg), vitamin B‐12 (500 microg), and vitamin B‐6 (10 mg)
Number of subjects: 276
Study 17284744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 16084158 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily
Number of subjects: 3152
Study 16084158 — intervention group
Group type: COMPARATOR
Intervention: Captopril 50 mg 3 times daily
Number of subjects: 3152
Study 12047326 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day triple therapy for H. pylori eradication
Number of subjects: 108
Study 12047326 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day triple therapy for H. pylori eradication
Number of subjects: 108
Study 12047326 — intervention group
Group type: COMPARATOR
Intervention: H. pylori stool antigen before therapy
Number of subjects: 108
Study 12047326 — intervention group
Group type: COMPARATOR
Intervention: H. pylori stool antigen after therapy
Number of subjects: 108
Study 9989681 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MJ (340 mL) alcohol (wine or beer)
Number of subjects: 52
Study 9989681 — intervention group
Group type: COMPARATOR
Intervention: fat (cream fruit juice), protein (protein fruit juice), carbohydrate (grape juice)
Number of subjects: 52
Study 9989681 — intervention group
Group type: COMPARATOR
Intervention: water
Number of subjects: 52
Study 9989681 — intervention group
Group type: COMPARATOR
Intervention: no preload
Number of subjects: 52
Study 8216442 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride (0.25 mg)
Number of subjects: 1
Study 8216442 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride (0.50 mg)
Number of subjects: 1
Study 8216442 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride (1.25 mg)
Number of subjects: 1
Study 8216442 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride (1.50 mg)
Number of subjects: 1
Study 3677789 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination inhaler therapy (salbutamol and beclomethasone dipropionate)
Number of subjects: 18
Study 3677789 — intervention group
Group type: COMPARATOR
Intervention: Separate inhaler therapy (salbutamol and beclomethasone dipropionate)
Number of subjects: 18
Study 29307750 — intervention group
Group type: EXPERIMENTAL
Intervention: MRSA isolates
Number of subjects: 173
Study 29307750 — intervention group
Group type: COMPARATOR
Intervention: MSSA isolates
Number of subjects: 173
Study 26413853 — intervention group
Group type: EXPERIMENTAL
Intervention: FTC/TDF (Tenofovir-Emtricitabine)
Number of subjects: 2499
Study 26413853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2499
Study 26413853 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination offered to individuals susceptible to HBV
Number of subjects: 2499
Study 24965573 — intervention group
Group type: COMPARATOR
Intervention: Baricitinib (1-20 mg single ascending doses, 2-20 mg QD, 5 mg BID for 10 or 28 days)
Number of subjects: 0
Study 24965573 — intervention group
Group type: COMPARATOR
Intervention: Baricitinib
Number of subjects: 0
Study 23046071 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 142
Study 23046071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 20530324 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta-1b 50 microg
Number of subjects: 372
Study 20530324 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta-1b 250 microg
Number of subjects: 372
Study 20530324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 20530324 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta-1b (both dosages)
Number of subjects: 372
Study 20530324 — intervention group
Group type: EXPERIMENTAL
Intervention: NAbs to IFNbeta-1b
Number of subjects: 372
Study 20530324 — intervention group
Group type: EXPERIMENTAL
Intervention: NAb status
Number of subjects: 372
Study 19107071 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-aspartyl glutamic acid (NAAGA) monotherapy over 4 weeks
Number of subjects: 102
Study 19107071 — intervention group
Group type: COMPARATOR
Intervention: Bi-therapy (NAAGA and Levocabastine during the first week, then NAAGA only for the next 3 weeks)
Number of subjects: 102
Study 16602173 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised counselling and follow‐up telephone calls from an exercise scientist (ES) without a pedometer (G3)
Number of subjects: 28
Study 16602173 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised counselling and follow‐up telephone calls from an exercise scientist (ES) with a pedometer (G2)
Number of subjects: 28
Study 16602173 — intervention group
Group type: COMPARATOR
Intervention: Brief verbal and written advice from a general practitioner (GP) (G1)
Number of subjects: 28
Study 16602173 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 28
Study 11933906 — intervention group
Group type: EXPERIMENTAL
Intervention: D/Sense 2 + Prime & Bond 2.1
Number of subjects: 16
Study 11933906 — intervention group
Group type: EXPERIMENTAL
Intervention: D/Sense 2 + Bistite II SC
Number of subjects: 16
Study 11933906 — intervention group
Group type: COMPARATOR
Intervention: Prime & Bond 2.1 (no D/Sense 2 treatment)
Number of subjects: 16
Study 11933906 — intervention group
Group type: COMPARATOR
Intervention: Bistite II SC (no D/Sense 2 treatment)
Number of subjects: 16
Study 12349021 — intervention group
Group type: EXPERIMENTAL
Intervention: Spermicidal preparations containing nonoxynol-9 (gel products with varying amounts)
Number of subjects: 1800
Study 12349021 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppository tablet and film preparation
Number of subjects: 1800
Study 8721468 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. ketorolac (30 mg)
Number of subjects: 70
Study 8721468 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ketorolac (30 mg)
Number of subjects: 70
Study 8721468 — intervention group
Group type: EXPERIMENTAL
Intervention: intrawound (i.w.) ketorolac (30 mg)
Number of subjects: 70
Study 8721468 — intervention group
Group type: EXPERIMENTAL
Intervention: p.o. ketorolac (30 mg)
Number of subjects: 70
Study 8721468 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ketorolac)
Number of subjects: 70
Study 1888644 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine 200 mg administered perorally
Number of subjects: 0
Study 1888644 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine (various doses)
Number of subjects: 0
Study 6356971 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg sublingual buprenorphine
Number of subjects: 74
Study 6356971 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg intramuscular buprenorphine
Number of subjects: 74
Study 6356971 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg intramuscular morphine
Number of subjects: 74
Study 6356971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 31138281 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular rehabilitation program (heating, aerobic exercise, muscle strengthening) for 45 min, three times a week, for 16 weeks.
Number of subjects: 40
Study 31138281 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy for 45 min, three times a week, for 16 weeks.
Number of subjects: 40
Study 28842370 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg methylprednisolone acetate (MP)
Number of subjects: 48
Study 28842370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 24528544 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 53
Study 24528544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 24528544 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 53
Study 24907224 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir (150 mg once daily, orally), peginterferon alfa 2a (180 μg once weekly, subcutaneous injection) or 2b (according to bodyweight), plus ribavirin (1000‐1200 mg/day or 800‐1400 mg/day, orally)
Number of subjects: 391
Study 24907224 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once daily, orally), peginterferon alfa 2a or 2b, plus ribavirin
Number of subjects: 391
Study 24907224 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir group
Number of subjects: 391
Study 24907224 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 391
Study 22925325 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus GG; ATCC 53103; 1 × 10(10) colony-forming units daily)
Number of subjects: 191
Study 22925325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 19757048 — intervention group
Group type: EXPERIMENTAL
Intervention: Balsalazide 3 g/d (n = 38)
Number of subjects: 86
Study 19757048 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 37)
Number of subjects: 86
Study 19757048 — intervention group
Group type: EXPERIMENTAL
Intervention: Balsalazide 3 g/d
Number of subjects: 86
Study 19757048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 17517301 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial sensory retraining exercises in conjunction with standard opening exercises
Number of subjects: 186
Study 17517301 — intervention group
Group type: COMPARATOR
Intervention: Standard opening exercises alone
Number of subjects: 186
Study 15364042 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (400 mg/day)
Number of subjects: 38
Study 15364042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 11435055 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous modified glucose-insulin-potassium infusion
Number of subjects: 48
Study 11435055 — intervention group
Group type: COMPARATOR
Intervention: Intermittent intravenous (IV) insulin injections
Number of subjects: 48
Study 9526936 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine (300 microg)
Number of subjects: 80
Study 9526936 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (i.m.) clonidine (300 microg)
Number of subjects: 80
Study 9526936 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine (300 microg)
Number of subjects: 80
Study 9526936 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 80
Study 10325270 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterosalpingography (HSG)
Number of subjects: 794
Study 10325270 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 794
Study 1972487 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (75 mg daily)
Number of subjects: 100
Study 1972487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 464807 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline hyclate 100 mg twice daily on postoperative days 5 through 10 and then 100 mg daily for six weeks
Number of subjects: 45
Study 464807 — intervention group
Group type: COMPARATOR
Intervention: No drug (control group)
Number of subjects: 45
Study 30876445 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic Support (PS)
Number of subjects: 13
Study 30876445 — intervention group
Group type: COMPARATOR
Intervention: Pelvic Constraint (PC)
Number of subjects: 13
Study 27914210 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT) using egg
Number of subjects: 30
Study 27914210 — intervention group
Group type: COMPARATOR
Intervention: Egg elimination (EE) group
Number of subjects: 30
Study 26002927 — intervention group
Group type: EXPERIMENTAL
Intervention: High coffee intake
Number of subjects: 93179
Study 26002927 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically derived high coffee intake
Number of subjects: 93179
Study 26002927 — intervention group
Group type: EXPERIMENTAL
Intervention: Per-allele meta-analysed odds ratios for type 2 diabetes
Number of subjects: 93179
Study 23899532 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1/cisplatin (CS)
Number of subjects: 1053
Study 23899532 — intervention group
Group type: COMPARATOR
Intervention: infusional 5-FU/cisplatin (CF)
Number of subjects: 1053
Study 22201659 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention started at the beginning of chemotherapy (EE)
Number of subjects: 66
Study 22201659 — intervention group
Group type: COMPARATOR
Intervention: Exercise intervention started at the completion of chemotherapy (CE)
Number of subjects: 66
Study 19502623 — intervention group
Group type: EXPERIMENTAL
Intervention: New onset atrial fibrillation (AF)
Number of subjects: 5745
Study 19502623 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin use in patients with AF at discharge
Number of subjects: 5745
Study 19502623 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation therapy at discharge
Number of subjects: 5745
Study 19502623 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy among patients with coronary stents
Number of subjects: 5745
Study 19502623 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation in patients at highest risk of stroke (CHADS(2) score >=2)
Number of subjects: 5745
Study 17313533 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrogram (EGM) method for AVD programming
Number of subjects: 28
Study 17313533 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive methods for AVD programming
Number of subjects: 28
Study 15251160 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg ibandronate
Number of subjects: 466
Study 15251160 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg ibandronate
Number of subjects: 466
Study 15251160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 466
Study 11334201 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxima PRF Plus
Number of subjects: 90
Study 11334201 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantum
Number of subjects: 90
Study 11334201 — intervention group
Group type: EXPERIMENTAL
Intervention: Affinity NT
Number of subjects: 90